Sherry A. Martin, MD: May 1, 2018

Where You Live Shouldn’t Determine How Long You Live

SHERRY A. MARTIN, MD

Vice President of Diabetes Global Medical Affairs at Eli Lilly and Company

 

Since 1900, the average life expectancy in the United States has increased to almost 80 years due in part to advances in healthcare. Yet, not everyone benefits equally from these advances. In fact, there are certain areas in Indianapolis where life expectancy can decrease by more than 14 years.  With this in mind, Indianapolis-based Eli Lilly and Company, a leading biopharmaceutical company, is launching a new local program, stemming from decades of work to improve health for people living in lower-income countries. The program aims to improve health, diabetes care and access to quality healthcare in three Indianapolis neighborhoods with significant health disparities and a high incidence of diabetes. In these three neighborhoods, there are an estimated 10,000 people living with diabetes with prevalence rates as high as 17.5 percent. Along with IU Fairbanks School of Public Health, Eskenazi Health and several community partners, Lilly’s program will use community health care workers to identify people with diabetes and connect them with quality care. The program will address cultural, social, environmental, economic and policy barriers identified by community members with the aim of reducing diabetes complications and risk factors, and has the potential for adoption by the entire Eskenazi health system and other communities and health systems across the U.S.

On Tuesday, May 1, Dr. Sherry Martin will be available for live interviews to discuss the potential benefits of this neighborhood-based, data-driven approach to addressing the diabetes epidemic. Dr. Martin will also discuss how this program directly supports Lilly’s 30X30 initiative, the company’s goal to improve access to quality health care for 30 million people in underserved communities every year by 2030.

 

About the Program

Lilly is collaborating with Indiana University’s Fairbanks School of Public Health and Eskenazi Health. Borrowing from Lilly’s global health efforts, the pilot will deploy a model that uses newly hired community health care workers to help identify people with diabetes and connect them with quality care. In addition, community members will help identify and propose solutions for cultural, social, environmental, economic and policy barriers that increase the risk for diabetes, such as the lack of health food options and public spaces for exercise.

About Sherry A. Martin, MD:

Sherry A. Martin, MD, is Vice President of Diabetes Global Medical Affairs at Eli Lilly and Company with oversight for Diabetes Medical Affairs and Global Medical Affairs Hosted Capabilities for all therapeutic areas. Dr. Martin has been extensively involved in Phase 3-4 clinical trial research and regulatory submissions and has co-authored multiple publications in peer-reviewed journals such as Diabetes Care, the Journal of Diabetes Science and Technology, and The New England Journal of Medicine. She is board-certified in Internal Medicine with a subspecialty certification in Endocrinology, Diabetes, and Metabolism. For 15 years prior to entering the pharmaceutical industry, she was a private practice clinical endocrinologist in Mississippi, Medical Director of the North Mississippi Diabetes Treatment Center, and served as an executive board member and Chair of the Medical Staff for North Mississippi Health Services, the largest rural hospital system in the United States.

Speak Your Mind

*